Glycogen synthase kinase 3b biology in bone and soft tissue sarcomas

作     者：Kensaku Abe Shingo Shimozaki Takahiro Domoto Norio Yamamoto Hiroyuki Tsuchiya Toshinari Minamoto Kensaku Abe;Shingo Shimozaki;Takahiro Domoto;Norio Yamamoto;Hiroyuki Tsuchiya;Toshinari Minamoto

作者机构：Department of Orthopaedic SurgeryGraduate School of Medical SciencesKanazawa UniversityKanazawa 920-8641Japan Division of Translational and Clinical OncologyCancer Research InstituteKanazawa UniversityKanazawa 920-0934Japan Shimozaki Orthopaedic HospitalHakusanIshikawa 924-0802Japan 

出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)

年 卷 期：2020年第6卷第1期

页      面：660-674页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Grants-in-Aid for Scientific Research from the Ministry of Education Culture Sports Science and Technology-Japan and from the Japan Society for the Promotion of Science(to Abe K Yamamoto N Tsuchiya H and Minamoto T) 

主　　题：Osteosarcoma rhabdomyosarcoma synovial sarcoma fibrosarcoma glycogen synthase kinase 3b 

摘      要：Bone and soft tissue sarcomas are malignant neoplasms probably originating from musculoskeletal and mesenchymal progenitor *** than 80 different histopathological subtypes are encountered in *** standard of care for sarcoma patients involves a multidisciplinary combination of surgery,anthracycline-based multiagent chemotherapy and ***,these are associated with adverse events and occasionally disappointing *** genomic-,biologically-,and immunologically-based therapies are still under evaluation in early-phase clinical ***,there are strong barriers to the development and clinical translation of new therapeutic *** is due to the rarity of these diseases,the broad spectrum of tumor subtypes with genetic and biological heterogeneity,and the wide variability in clinical manifestation,response to treatment and prognosis.A potential approach toward overcoming this barrier is to identify therapeutic targets that cover multiple sarcoma *** synthase kinase 3b(GSK3b)has emerged as a common therapeutic target in more than 25 different cancer *** we review the evidence for tumor-promoting roles of GSK3b in the major types of bone and soft tissue sarcomas including osteosarcoma,rhabdomyosarcoma,synovial sarcoma,and *** this review,we describe the therapeutic effects of inhibiting GSK3b in these sarcoma types,while also protecting healthy cells and tissues from detrimental effects associated with conventional therapies,such as doxorubicin-induced ***,we highlight GSK3b as a potential therapeutic target spanning multiple sarcoma types.